
THERAPEUTIC DRUG MONITORING OF CEFTAZIDIME/ AVIBACTAM ADMINISTERED BY CONTINUOUS INFUSION: PK/PD TARGET | Continuous | Co

D Fresan¹, S Luque², <u>J Miedes</u>², C Bosch², A Benítez-Cano², L Sorlí², M. De-Antonio², N Prim³, V Vega³, J.P Horcajada², S Grau²

¹Hospital Universitario de Navarra — Pamplona (Spain) ²Parc de Salut Mar — Barcelona (Spain) ³Laboratori de Referencia de Catalunya - Barcelona (Spain) _____

BACKGROUND AND IMPORTANCE



AIM AND OBJECTIVES

To analyze the correlation between PK/PD target attainment of CAZ/AVI administered by CI, clinical outcomes and toxicity.

MATERIALS AND METHODS

Patients treated with CI of CAZ/AVI undergoing TDM of the CAZ plasma concentrations were included. Definitions:

- ✓ CAZ/AVI PK/PD target: time that free concentrations remain 4 times above the MIC of the causative pathogen (%fT>4xMIC). (MIC: 8 mg/L assumed if real one not available)
- ✓ Overexposure: %fT>10xMIC
- ✓ **Clinical cure:** disappearance of all signs and symptoms related to the infection and no requirement for additional antibiotic treatment (except as part of de-escalation strategy) initiation for the disease to be investigated within 48 h after completion of the study drug
- ✓ Thirty-day all cause mortality: death from any cause during the 30 days following the end of treatment

RESULTS

- n:31 patients (28 males, median (range) age of 64 (37-78) years)
- 26 directed treatments (21 XDR-PA and 5 ESBL-K.pneumoniae) and 5 empirical
- √83.9% (n:26) achieved the PK/PD target (15 %fT>10xMIC). Only 4 (26.6%) overexposed patients presented adverse reactions (3 increased liver enzymes and 1 thrombocytopenia).
- √67.7% (n:21) achieved clinical cure, 18 (85.7%) of which achieved the PK/PD target. Higher frequency of patients with a %fT>4xMIC achieved clinical cure (18/26 (69.2%) in patients with clinical cure vs 2/5 (40%) with clinical failure, p= 0.686).
- ✓ 30-day all-cause mortality: 19.4 % (6 patients). Lower mortality rate in patients that achieved a %fT>4xMIC (14.8% in patients who survived vs 50% in those who died, p=0.096).

CONCLUSION AND RELEVANCE

CI seems a useful strategy to reach the PK/PD target of CAZ/AVI. Few patients with overexposure presented adverse events. There seems to be a correlation between PK/PD target attainment, clinical cure and 30-day all-cause mortality but larger studies with bigger samples are needed.



Abstract number: 4CPS-031

ATC code:J01- Antibacterials for systemic use